NASDAQ:STOKStoke Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stoke Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.34 -0.49 (-2.06 %) (As of 07/1/2020 04:00 PM ET) Add Compare Share Today's Range$22.87Now: $23.34▼$23.8050-Day Range$22.54MA: $25.40▼$29.7352-Week Range$15.82Now: $23.34▼$39.04Volume109,057 shsAverage Volume191,169 shsMarket Capitalization$769.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.50, Stoke Therapeutics has a potential upside of 56.4% from its current price of $23.34.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesStoke Therapeutics has received 42 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStoke Therapeutics has received 34 “underperform” votes. (Add your “underperform” vote.)Community SentimentStoke Therapeutics has received 55.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stoke Therapeutics and other stocks. Vote “Outperform” if you believe STOK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STOK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $846,656.00 in company stock.Percentage Held by Insiders54.60% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -12.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -12.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STOK Previous Symbol CUSIPN/A CIKN/A Webwww.stoketherapeutics.com Phone781-430-8200Debt Debt-to-Equity RatioN/A Current Ratio39.56 Quick Ratio39.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.86 per share Price / Book3.40Profitability EPS (Most Recent Fiscal Year)($1.80) Net Income$-32,330,000.00 Net MarginsN/A Return on Equity-16.47% Return on Assets-16.10%Miscellaneous Employees44 Outstanding Shares32,970,000Market Cap$769.52 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:STOK Rates by TradingView Receive STOK News and Ratings via Email Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions How has Stoke Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STOK stock has increased by 18.3% and is now trading at $23.34. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Stoke Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stoke Therapeutics. When is Stoke Therapeutics' next earnings date? Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Stoke Therapeutics. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics (NASDAQ:STOK) announced its earnings results on Friday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.02. View Stoke Therapeutics' earnings history. What price target have analysts set for STOK? 7 equities research analysts have issued 1 year price objectives for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $46.00. On average, they anticipate Stoke Therapeutics' share price to reach $36.50 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price. View analysts' price targets for Stoke Therapeutics. Has Stoke Therapeutics been receiving favorable news coverage? News headlines about STOK stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stoke Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Stoke Therapeutics. Who are some of Stoke Therapeutics' key competitors? Some companies that are related to Stoke Therapeutics include Alkermes (ALKS), Axsome Therapeutics (AXSM), CytoDyn (CYDY), Karuna Therapeutics (KRTX), Insmed (INSM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Opko Health (OPK), IGM Biosciences (IGMS), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), TG Therapeutics (TGTX) and Uniqure (QURE). View all competitors. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Akero Therapeutics (AKRO), LogicBio Therapeutics (LOGC), Precision BioSciences (DTIL), Gilead Sciences (GILD), Atreca (BCEL), Homology Medicines (FIXX) and Harpoon Therapeutics (HARP). Who are Stoke Therapeutics' key executives? Stoke Therapeutics' management team includes the following people: Dr. Edward M. Kaye, CEO & Director (Age 70)Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)Ms. Isabel Aznarez, Co-Founder, VP & Head of BiologyMr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52) When did Stoke Therapeutics IPO? (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Stoke Therapeutics' stock symbol? Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK." How do I buy shares of Stoke Therapeutics? Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Stoke Therapeutics' stock price today? One share of STOK stock can currently be purchased for approximately $23.34. How big of a company is Stoke Therapeutics? Stoke Therapeutics has a market capitalization of $769.52 million. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe. What is Stoke Therapeutics' official website? The official website for Stoke Therapeutics is www.stoketherapeutics.com. How can I contact Stoke Therapeutics? Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected] This page was last updated on 7/2/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
